Gemphire Therapeutics (NASDAQ:GEMP) released its earnings results on Thursday. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.47) by $0.04, Fidelity Earnings reports.
Shares of GEMP stock opened at $1.27 on Friday. The company has a market cap of $20.11 million, a price-to-earnings ratio of -0.39 and a beta of 2.48. The company has a debt-to-equity ratio of 0.50, a quick ratio of 4.64 and a current ratio of 4.64. Gemphire Therapeutics has a fifty-two week low of $0.83 and a fifty-two week high of $11.43.
A number of research analysts have weighed in on the stock. Jefferies Financial Group cut shares of Gemphire Therapeutics from a “buy” rating to a “hold” rating and set a $15.00 price target on the stock. in a research report on Monday, August 13th. Zacks Investment Research cut shares of Gemphire Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 15th. Roth Capital lifted their price target on shares of Gemphire Therapeutics from $30.00 to $40.00 and gave the company a “buy” rating in a research report on Friday, July 27th. ValuEngine raised shares of Gemphire Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Finally, Raymond James cut shares of Gemphire Therapeutics from an “outperform” rating to a “market perform” rating and set a $22.00 price target on the stock. in a research report on Tuesday, August 7th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $17.13.
Gemphire Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and non-alcoholic steatohepatitis (NASH). It is developing gemcabene, a novel, once-daily, oral therapy, for high risk cardiovascular patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy, and for those patients who present with NASH.
Recommended Story: Leveraged Buyout (LBO) Explained
Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.